Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years

Abstract

Combined PDT and ranibizumab injection the same day was well tolerated in all patients. Eighty-four percent of patients had stable or improved vision at month 24.

One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration

“…The TORPEDO trial, which examined the effects of combined PDT and ranibizumab injection on the same day, showed that the mean visual acuity improved by 7.2 letters and 84% of the patients had stable or improved vision at 2 years [12]. It also showed that the mean CMT decreased by 146  μ m [12]. These results were comparable to ours although differences in study design and sample size prohibited direct comparison.…”

Current Knowledge and Trends in Age-Related Macular Degeneration

“…122 In a recent press release, the company informed that a multicenter Phase 2 study performed in Europe, The IRay Plus Anti-VEGF Treatment For Patients With Wet AMD (INTREPID, NCT01016873), 123 has met its primary end point of reducing the need for anti-VEGF drug injections for patients with wet AMD. 133,134 The main differences were that in the PROTECT trial, PDT was administered using standard fluence and four loading doses of ranibizumab, whereas in the TORPEDO trial, a reduced fluence PDT was used with three loading doses of ranibizumab. A more detailed presentation of the results is expected to be presented during the EURETINA Congress in Milan, Italy, in September of this year.…”

“…The study was a shamcontrolled double-masked study that assessed the effectiveness and safety of one-time radiation therapy in conjunction with as-needed anti-VEGF intravitreal injections of ranibizumab. 133,134 Both studies used a PRN scheme for ranibizumab retreatment thereafter. 123,124 Photodynamic therapy and steroids.…”

“…A more detailed presentation of the results is expected to be presented during the EURETINA Congress in Milan, Italy, in September of this year. 133,134 The SUMMIT clinical trial program was a set of three, randomized, prospective, clinical trials sponsored by Novartis International (Basel, Switzerland) aimed to compare the combined therapy of PDT and ranibizumab against ranibizumab alone; however, only two of them were actually intended for the treatment of wet AMD. In the year 2000, photodynamic therapy (PDT) became the first FDA-approved treatment for advanced cases of neovascular AMD by being the first treatment to effectively prevent vision loss.…”

Combined Therapies to Treat CNV in AMD: PDT + Anti-VEGF

“…Spielberg treated 27 cases with reduced-fluence PDT followed by intravitreal Ranibizumab on the same day. Retreatments administered with Ranibizumab during the 24-month follow-up stabilized 84% of the patients' vision or improved it at month 24 (Spielberg & Leys, 2010). A prospective comparative study was performed on 85 AMD patients divided into two groups, one treated with intravitreal Bevacizumab (IVB) monotherapy and the other with IVB combined with low-fluence PDT (300 mW/cm2 for 83 s, 25 J/cm2 ) with a twelve-month follow-up.…”